Latest News and Press Releases

MELBOURNE, Australia and SAN FRANCISCO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...

MELBOURNE, Australia and SAN FRANCISCO, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...

MELBOURNE, Australia and SAN FRANCISCO, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...

Highlights: ATH434-201 Phase 2 study on track to complete enrollment in Q3 2023 with top-line data expected by the end of 2024 in individuals with Multiple System Atrophy (MSA)ATH434-201 Phase 2 Data...

ATH434-201 Trial on Track to Complete Enrollment in Q3 2023 Top-Line Data Expected by the End of 2024 MELBOURNE, Australia and SAN FRANCISCO, July 26, 2023 (GLOBE NEWSWIRE) -- Alterity...

MELBOURNE, Australia and SAN FRANCISCO, June 21, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...

- ATH434 now being evaluated in early and more advanced Multiple System Atrophy - - New trial expected to generate data before ongoing Phase 2 trial - MELBOURNE, Australia and SAN FRANCISCO, May...

MELBOURNE, Australia and SAN FRANCISCO, May 19, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative...

MELBOURNE, Australia and SAN FRANCISCO, May 10, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing...

Highlights: Continued expansion of ATH434 Phase 2 Clinical Trial with sites open for recruitment in five countriesParticipants in the US and Europe received first dose as part of the ATH434 Phase 2...